Literature DB >> 17994109

CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

M Rajesh1, P Mukhopadhyay, G Haskó, J W Huffman, K Mackie, P Pacher.   

Abstract

BACKGROUND AND
PURPOSE: Vascular smooth muscle proliferation and migration triggered by inflammatory stimuli are involved in the development and progression of atherosclerosis and restenosis. Cannabinoids may modulate cell proliferation in various cell types through cannabinoid 2 (CB2) receptors. Here, we investigated the effects of CB2 receptor agonists on TNF-alpha-induced proliferation, migration and signal transduction in human coronary artery smooth muscle cells (HCASMCs). EXPERIMENTAL APPROACH: HCASMCs were stimulated with TNF-alpha. Smooth muscle proliferation was determined by the extent of BrdU incorporation and the migration was assayed by modified Boyden chamber. CB2 and/or CB1 receptor expressions were determined by immunofluorescence staining, western blotting, RT-PCR, real-time PCR and flow cytometry. KEY
RESULTS: Low levels of CB2 and CB1 receptors were detectable in HCASMCs compared to the high levels of CB2 receptors expressed in THP-1 monocytes. TNF-alpha triggered up to approximately 80% increase (depending on the method used) in CB2 receptor mRNA and/or protein expression in HCASMCs, and induced Ras, p38 MAPK, ERK 1/2, SAPK/JNK and Akt activation, while increasing proliferation and migration. The CB2 agonists, JWH-133 and HU-308, dose-dependently attenuated these effects of TNF-alpha. CONCLUSIONS AND IMPLICATIONS: Since the above-mentioned TNF-alpha-induced phenotypic changes are critical in the initiation and progression of atherosclerosis and restenosis, our findings suggest that CB2 agonists may offer a novel approach in the treatment of these pathologies by decreasing vascular smooth muscle proliferation and migration.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17994109      PMCID: PMC2219520          DOI: 10.1038/sj.bjp.0707569

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  52 in total

1.  Identification and functional characterization of brainstem cannabinoid CB2 receptors.

Authors:  Marja D Van Sickle; Marnie Duncan; Philip J Kingsley; Abdeslam Mouihate; Paolo Urbani; Ken Mackie; Nephi Stella; Alexandros Makriyannis; Daniele Piomelli; Joseph S Davison; Lawrence J Marnett; Vincenzo Di Marzo; Quentin J Pittman; Kamala D Patel; Keith A Sharkey
Journal:  Science       Date:  2005-10-14       Impact factor: 47.728

Review 2.  Cannabinoid-based drugs as anti-inflammatory therapeutics.

Authors:  Thomas W Klein
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 3.  Inflammation, atherosclerosis, and coronary artery disease.

Authors:  Göran K Hansson
Journal:  N Engl J Med       Date:  2005-04-21       Impact factor: 91.245

4.  Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice.

Authors:  Sabine Steffens; Niels R Veillard; Claire Arnaud; Graziano Pelli; Fabienne Burger; Christian Staub; Meliha Karsak; Andreas Zimmer; Jean-Louis Frossard; François Mach
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

5.  Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.

Authors:  Katarzyna Maresz; Erica J Carrier; Eugene D Ponomarev; Cecilia J Hillard; Bonnie N Dittel
Journal:  J Neurochem       Date:  2005-08-08       Impact factor: 5.372

6.  Regulation of vascular smooth muscle cell proliferation: role of NF-kappaB revisited.

Authors:  Felix B Mehrhof; Ruth Schmidt-Ullrich; Rainer Dietz; Claus Scheidereit
Journal:  Circ Res       Date:  2005-04-14       Impact factor: 17.367

7.  Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells.

Authors:  Sean D McAllister; Calvin Chan; Ryan J Taft; Tri Luu; Mary E Abood; Dan H Moore; Ken Aldape; Garret Yount
Journal:  J Neurooncol       Date:  2005-08       Impact factor: 4.130

Review 8.  MAP kinases and cell migration.

Authors:  Cai Huang; Ken Jacobson; Michael D Schaller
Journal:  J Cell Sci       Date:  2004-09-15       Impact factor: 5.285

9.  Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models.

Authors:  Ji Zhang; Cyrla Hoffert; Huy Khang Vu; Thierry Groblewski; Sultan Ahmad; Dajan O'Donnell
Journal:  Eur J Neurosci       Date:  2003-06       Impact factor: 3.386

10.  Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells.

Authors:  Cristina Zoratti; Dijle Kipmen-Korgun; Karin Osibow; Roland Malli; Wolfgang F Graier
Journal:  Br J Pharmacol       Date:  2003-11-24       Impact factor: 8.739

View more
  55 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Here today, gone tomorrow…and back again? A review of herbal marijuana alternatives (K2, Spice), synthetic cathinones (bath salts), kratom, Salvia divinorum, methoxetamine, and piperazines.

Authors:  Christopher D Rosenbaum; Stephanie P Carreiro; Kavita M Babu
Journal:  J Med Toxicol       Date:  2012-03

3.  Pleiotropic effects of the CB2 cannabinoid receptor activation on human monocyte migration: implications for atherosclerosis and inflammatory diseases.

Authors:  Pál Pacher; Zoltán Ungvári
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-18       Impact factor: 4.733

Review 4.  CB1 cannabinoid receptor inhibition: promising approach for heart failure?

Authors:  Partha Mukhopadhyay; Rajesh Mohanraj; Sándor Bátkai; Pál Pacher
Journal:  Congest Heart Fail       Date:  2008 Nov-Dec

5.  Anti-inflammatory cannabinoids in diet: Towards a better understanding of CB(2) receptor action?

Authors:  Jürg Gertsch
Journal:  Commun Integr Biol       Date:  2008

6.  Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; György Haskó; Pál Pacher
Journal:  Biochem Biophys Res Commun       Date:  2008-11-06       Impact factor: 3.575

7.  Indole compounds with N-ethyl morpholine moieties as CB2 receptor agonists for anti-inflammatory management of pain: synthesis and biological evaluation.

Authors:  Jiaojiao Li; Jing Ji; Ruibo Xu; Zhengfu Li
Journal:  Medchemcomm       Date:  2019-09-17       Impact factor: 3.597

Review 8.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 9.  The emerging role of the endocannabinoid system in cardiovascular disease.

Authors:  Pál Pacher; Sabine Steffens
Journal:  Semin Immunopathol       Date:  2009-04-09       Impact factor: 9.623

Review 10.  Endocannabinoids and the heart.

Authors:  C Robin Hiley
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.